Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects with Type 2 Diabetes Mellitus Protocol # WEL-A-U307

Pediatrics, Diabetes
Holley Allen, MD, MSPH
Baystate Children's Specialty Center
50 Wason Ave
Springfield, MA

The purpose of this study is to evaluate the safety and tolerability of Welchol® (colesevelam HCl) as a treatment for children/adolescents with Type 2 Diabetes.

  • Type 2 Diabetes
  • Ages 10-17
  • A1C 7.0-10.0%
  • No insulin therapy (ever or within > 14 days of study screening)
Rebecca Feinberg